Exclusive Content
How a Foreign Biotech Leveraged China’s MAH System to Launch a Biosimilar in Shanghai
How a Foreign Biotech Leveraged China's MAH System to Launch a Biosimilar in Shanghai In 2021, a mid-sized European biotech, BioVantis AG , became one
Suzhou BioBay vs Zhangjiang Hi-Tech Park: Which China Biotech Park Is Best for Foreign R&D?
Suzhou BioBay vs Zhangjiang Hi-Tech Park: Which China Biotech Park Is Best for Foreign R&D? In China’s crowded field of 160+ biotech parks, Suzhou Bio
Can I sue a Chinese company outside of China for breach of contract?
Can I sue a Chinese company outside of China for breach of contract? | CG360 Commercial Law FAQ Can I sue a Chinese company outside of China for breac
How long does commercial litigation take in Chinese courts?
How long does commercial litigation take in Chinese courts? | CG360 Commercial Law FAQ How long does commercial litigation take in Chinese courts? Und
NMPA vs FDA: Which Drug Approval Pathway Is Faster for Foreign Biotech in China?
NMPA vs FDA: Which Drug Approval Pathway Is Faster for Foreign Biotech in China? For foreign biotech companies considering China market entry, the cho
How does China’s new Drug Marketing Authorization Holder (MAH) system benefit foreign biotech companies?
How China's Drug Marketing Authorization Holder (MAH) System Unlocks Market Access for Foreign Biotechs China’s Drug Marketing Authorization Holder (M